Cargando…

Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma

BACKGROUND: With the rapid development of next-generation sequencing (NGS) technologies, researchers are making efforts to reveal the genomic landscape of multiple myeloma (MM). However, the clinical significance of many mutations remains poorly defined due to the genetic heterogeneity of MM. To sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lina, Zhang, Run, Wang, Jing, Chen, Ying, Qiao, Chun, Shi, Qinglin, Jin, Yuanyuan, Shen, Xuxing, Li, Jianyong, Chen, Lijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308335/ https://www.ncbi.nlm.nih.gov/pubmed/35870987 http://dx.doi.org/10.1186/s13148-022-01314-7

Ejemplares similares

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Baohuoside I Inhibits Tumor Angiogenesis in Multiple Myeloma via the Peroxisome Proliferator–Activated Receptor γ/Vascular Endothelial Growth Factor Signaling Pathway
por: Chen, Ying, et al.
Publicado: (2022)

High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics
por: Xia, Yuan, et al.
Publicado: (2023)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

Survival trends and prognostic factors for patients with extramedullary plasmacytoma: A population-based study
por: Shen, Xuxing, et al.
Publicado: (2022)

Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
por: Shen, Xuxing, et al.
Publicado: (2021)

TRPV2-induced Ca(2+)-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma
por: Bai, Hua, et al.
Publicado: (2018)

The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
por: Yu, Wenjun, et al.
Publicado: (2016)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
por: Xia, Yuan, et al.
Publicado: (2023)

Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study
por: Shen, Xuxing, et al.
Publicado: (2020)

Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review
por: Shen, Haorui, et al.
Publicado: (2020)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk
por: Waller, Rosalie G., et al.
Publicado: (2018)

Clinical features of multiple myeloma patients with isolated extramedullary relapse
por: Qu, Xiaoyan, et al.
Publicado: (2018)

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
por: Ruiz-Heredia, Yanira, et al.
Publicado: (2021)

Progress in the identification of gene mutations involved in multiple myeloma
por: Hu, Ying, et al.
Publicado: (2019)

Clinical prognostic implications of EPB41L4A expression in multiple myeloma
por: Zhang, Weilong, et al.
Publicado: (2020)

Fractal Characteristics of May-Grünwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma
por: Ferro, Daniela P., et al.
Publicado: (2011)

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
por: Evers, Marietheres, et al.
Publicado: (2023)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
por: Lebel, Eyal, et al.
Publicado: (2022)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

A prognostic model for patients with primary extramedullary multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma
por: Chakraborty, Chandraditya, et al.
Publicado: (2022)

Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma
por: Chen, Xinyi, et al.
Publicado: (2017)

Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance
por: Qu, Xiaoyan, et al.
Publicado: (2015)

Prognostic significance of FSCN family in multiple myeloma
por: Deng, Cong, et al.
Publicado: (2021)

Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma
por: Song, Ik-Chan, et al.
Publicado: (2015)

Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma
por: Luo, Tiancheng, et al.
Publicado: (2020)

Prognostic factors and classification in multiple myeloma.
por: San Miguel, J. F., et al.
Publicado: (1989)

A prognostic index for multiple myeloma.
por: Grignani, G., et al.
Publicado: (1996)

The Evolution of Prognostic Factors in Multiple Myeloma
por: Hanbali, Amr, et al.
Publicado: (2017)

Immunological Prognostic Factors in Multiple Myeloma
por: Bębnowska, Dominika, et al.
Publicado: (2021)

A novel prognostic model based on pyroptosis-related genes for multiple myeloma
por: Zhang, Cuiling, et al.
Publicado: (2023)

Ras oncogene mutation in multiple myeloma
Publicado: (1989)

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma
por: Ordoñez, Raquel, et al.
Publicado: (2020)

Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance
por: Chen, Hai-Fei, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_h5iq50d5gqj3cvcsvss15h75f0